Over the last few months, PDCI Market Access Inc., Connex Health and H3 Consulting have undertaken an initiative to better understand the Canadian private payer product listing agreement (PLA) landscape and how it has evolved ... Read More
At PDCI Market Access Inc., our vision at PDCI is to be your most trusted and valued pricing and reimbursement strategic partner. To ensure we continue to meet the strategic needs of our customers in the face of the ever-changing Canadian reimbursement landscape, we’ve expanded our Health Economic ... Read More
PDCI Market Access is
pleased to release our premier issue of PDCI
Market Access INSIGHTS online journal to
our Market Access Toolkit subscribers. The articles in our first issue provide
deep dives into:
Planning and budgeting PSPs during the pandemic,New data and new perspectives on private insurers and ... Read More
The August 2020 issue of Cell & Gene Therapy Insights, has a focus on Market access: evolving commercialization trends and strategies. PDCI Market Access’ very own Neil Palmer is featured as a guest editor and the author of the article, Under construction: roadmaps for HTA, pricing and ... Read More
PDCI Market Access Inc. is pleased to share its best practices infographic focused on Requesting Reconsideration under the Canadian Agency for Drugs and Technologies in Health (CADTH) Procedures for the Common Drug Review (CDR). While optional and only appropriate in select circumstances, manufacturers should not overlook this potential opportunity ... Read More
As PDCI announced earlier today, the PMPRB has issued the second draft of the PMPRB Guidelines to support the implementation of Patented Medicines Regulations (Regulations) changes coming unto force on January 1, 2021. This draft is now available for a 30-day Notice and Comment Period. Written feedback ... Read More
PMPRB Guidelines
and Regulations Update
As first disclosed by PDCI last week, the PMPRB Board Chair officially confirmed that the amended Patented Medicines Regulations (“Regulations”) will now come into force on January 1, 2021. These Regulations were published in Canada Gazette II in August 2019 with ... Read More
REMINDER: As announced last month, PDCI and its research partners are studying the private payer product listing agreement (PLA) landscape in Canada by surveying pharmaceutical manufacturers and private payers about their ... Read More
